Future G protein-coupled receptor targets for treatment of heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 4, 2009, Pages 328-338

  Rengo, Giuseppe ^a   Lymperopoulos, Anastasios ^a   Koch, Walter J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR KINASE; BETA ARRESTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; METOPROLOL; PHOSPHODIESTERASE IV;

DRUG MECHANISM; ENZYME INHIBITION; GENE THERAPY; HEART FAILURE; HEART MUSCLE CELL; HUMAN; NEUROENDOCRINOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 67651113673     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0033-5     Document Type: Review

References (49)

1. Pierce KL, Premont RT, Lefkowitz RJ: Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002, 3: 639-650.
2. Adorisio R, DeLuca L, Rossi J, Gheorghiade M: Pharmacological treatment of chronic heart failure. Heart Fail Rev 2006, 11:109-123.
3. Bylund DB, Eikenberg DC, Hieble JP, et al.: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994, 46:121-136.
4. Rockman HA, Koch WJ, Lefkowitz RJ: Seven-transmembrane-spanning receptors and heart function. Nature 2002, 415:206-212.
5. Cohn JN, Levine TB, Olivari MT, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
6. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ: Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 1991, 60:653-688.
7. Bristow MR: B-Adrenergic receptor blockade in chronic HF. Circulation 2000, 101:558-569.
8. Communal C, Singh K, Sawyer DB, Colucci WS: Opposing effects of b1- and b2-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein. Circulation 1999, 100:2210-2212.
9. Zhu WZ, Zheng M, Koch WJ, et al.: Dual modulation of cell survival and cell death by b2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A. 2001, 98:1607-1612.
10. Liggett SB, Tepe NM, Lorenz JN, et al.: Early and delayed consequences of b2-adrenergic receptor overexpression in mouse hearts: Critical role for expression level. Circulation 2000, 101:1707-1714.
11. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in b1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999, 96:7059-7064.
12. Ahmet I, Krawczyk M, Heller P, et al.: Beneficial effects of chronic pharmacological manipulation of b-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 2004, 110:1083-1090.
13. Maurice JP, Hata JA, Shah AS, et al.: Enhancement of cardiac function after adenoviral-mediated in vivo intra-coronary b2-adrenergic receptor gene delivery. J Clin Invest 1999, 104:21-29.
14. DeGeorge BR Jr, Gao E, Boucher M, et al.: Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 2008, 117:1378-1387.
15. Petrofski JA, Koch WJ: The b-adrenergic receptor kinase (bARK1) in heart failure. J Mol Cell Cardiol 2003, 35:1167-1174.
16. Lefkowitz RJ, Shenoy SK: Transduction of receptor signals by b-arrestins. Science 2005, 308:512-517.
17. Vinge LE, Raake PW, Koch WJ: Gene therapy in heart failure. Circ Res 2008, 102:1458-1470.
18. Koch WJ, Inglese J, Stone WC, Lefkowitz RJ: The binding site for the bg subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem 1993, 268:8256-8260.
19. Koch WJ, Rockman HA, Samama P, et al.: Cardiac function in mice overexpressing the b-adrenergic receptor kinase or a bARK inhibitor. Science 1995, 268:1350-1353.
20. Shah AS, White DC, Emani S, et al.: In vivo ventricular gene delivery of a b-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001, 103:1311-1316.
21. White DC, Hata JA, Shah AS, et al.: Preservation of myocardial b-adrenergic receptor delays the development of heart failure following myocardial infarction. Proc Natl Acad Sci U S A 2000, 97:5428-5433.
22. Williams ML, Hata JA, Schroder J, et al.: Targeted b-adrenergic receptor kinase (bARK1) inhibition by gene transfer in failing human hearts. Circulation 2004, 109:1590-1593.
23. Rengo G, Lymperopoulos A, Zincarelli C, et al.: Myocardial adeno-associated virus serotype 6-bARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009, 119:89-98.
24. Rockman HA, Choi DJ, Akhter SA, et al.: Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 1998, 273:18180-18184.
25. Raake PW, Vinge LE, Gao E, et al.: G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 2008, 103:413-422.
26. Dzimiri N, Muiya P, Andres E, Al-Halees Z: Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol 2004, 489:167-177.
27. Eckhart AD, Duncan SJ, Penn RB, et al.: Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 2000, 86:43-50.
28. Liggett SB, Cresci S, Kelly RJ, et al.: A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14:510-517.
29. Noma T, Lemaire A, Naga Prasad SV, et al.: Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007, 117:2396-2398.
30. Martini JS, Raake P, Vinge LE, et al.: Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A 2008, 105:12457-12462.
31. Rajagopal K, Whalen EJ, Violin JD et al.: B-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A 2006, 103:16284-16289.
32. Richter W, Day P, Agrawal R, et al.: Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J 2008, 27:384-393.
33. Brede M, Nagy G, Philipp M, et al.: Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol 2003, 17:1640-1646.
34. Lymperopoulos A, Rengo G, Funakoshi H, et al.: Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007, 13:315-323.
35. Lymperopoulos A, Rengo G, Zincarelli C, et al.: Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol Ther 2008, 16:302-307.
36. Willenbrock R, Philipp S, Mitrovic V, Dietz R: Neurohumoral blockade in CHF management. J Renin Angiotensin Aldosterone Syst 2000, 1(Suppl 1):24-30.
37. Berk BC: Angiotensin type 2 reAeptor (AT2R): a challenging twin. Sci STKE 2003, 181:PE16.
38. Matsumoto T, Wada A, Tsutamoto T, et al.: Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003, 107:2555-2558.
39. Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
40. Cruden NL, Witherow FN, Webb DJ, et al.: Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 2004, 24:1043-1048.
41. Violin JD, Lefkowitz RJ: Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007, 28:416-422.
42. Modlinger PS, Welch WJ: Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 2003, 12:497-502.
43. Gottlieb SS, Brater DC, Thomas I, et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105:1348-1353.
44. Headrick JP, Willems L, Ashton KJ, et al.: Ischaemic tolerance in aged mouse myocardium: The role of adenosine and effects of A1 adenosine receptor overexpression. J Physiol 2003, 549:823-833.
45. Liao Y, Takashima S, Asano Y, et al.: Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 2003, 93:759-766.
46. Funakoshi H, Chan TO, Good JC, et al.: Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 2006, 114:2240-2250.
47. Chan TO, Funakosji H, Song K, et al.: Cardiac-restricted overexpression of the A2A-adenosine receptor in FVB mice transiently increases contractile performance and rescues the heart failure phenotype in mice overexpressing the A1-adenosine receptor. Clin Trans Sci 2008, 1:126-133.
48. Kirkby NS, Hadoke PWF, Bagnall AJ, Webb DJ: The endothelin system as therapeutic target in cardiovascular disease: Great expectations or bleak house? Br J Pharmacol 2008, 153:1105-1119.
49. D'Orléans-Juste P, Labonté J, Bkaily G, et al.: Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 2002, 221-238.